RGEN vs TKNO
RGEN: Repligen provides critical, high-efficiency bioprocessing technologies and systems that enable biopharmaceutical companies to manufacture life-saving biological drugs. TKNO: Alpha Teknova is a specialized manufacturer of essential reagents and custom chemical solutions that accelerate the development and production of biopharmaceuticals and diagnostic products.
Side-by-side fundamentals
| Metric | RGEN | TKNO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $140.09 | $5.24 | |
| Market cap as of 2026-07-23 | $7.9B | $281M | |
| P/E as of 2026-07-23 | 153.85 | n/a | |
| PEG as of 2026-07-23 | 6.61 | n/a | |
| Net margin as of 2026-07-23 | +6.7% | -41.1% | RGEN higher |
| Gross margin as of 2026-07-23 | +53.1% | +34.0% | RGEN higher |
| Operating margin as of 2026-07-23 | +6.7% | -39.0% | RGEN higher |
| ROE as of 2026-07-23 | +2.5% | -24.3% | RGEN higher |
| ROA as of 2026-07-23 | +1.8% | -16.3% | RGEN higher |
| Debt / equity as of 2026-07-23 | 0.26 | 0.20 | TKNO lower |
| Revenue growth (YoY) as of 2026-07-23 | +18.2% | +9.3% | RGEN higher |
| Revenue CAGR (3y) SEC XBRL | +30.5% | -0.7% | RGEN higher |
| Beta as of 2026-07-23 | 1.03 | 0.67 | |
| 1-year return as of 2026-07-22 close | +22.8% | +29.9% | TKNO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.